Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel DiseaseBusiness Wire • 07/25/24
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia AGlobeNewsWire • 07/17/24
Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US MarketBusiness Wire • 07/10/24
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDGlobeNewsWire • 07/03/24
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMGlobeNewsWire • 06/26/24
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVCBenzinga • 06/26/24
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive CommitteeGlobeNewsWire • 06/21/24
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranGlobeNewsWire • 06/21/24
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological DiseasesGlobeNewsWire • 06/18/24